Sesen Bio (STU:PCBK) Scaled Net Operating Assets : -0.04 (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Sesen Bio Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sesen Bio's operating assets for the quarter that ended in Dec. 2022 was €21.01 Mil. Sesen Bio's operating liabilities for the quarter that ended in Dec. 2022 was €29.25 Mil. Sesen Bio's Total Assets for the quarter that ended in Sep. 2022 was €201.72 Mil. Therefore, Sesen Bio's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2022 was -0.04.

Sesen Bio Scaled Net Operating Assets Historical Data

The historical data trend for Sesen Bio's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio Scaled Net Operating Assets Chart

Sesen Bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.09

-0.69

-0.49

0.08

-0.04

Sesen Bio Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.04	0.01	-	-0.08	-0.04

Competitive Comparison of Sesen Bio's Scaled Net Operating Assets

For the Biotechnology subindustry, Sesen Bio's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sesen Bio's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sesen Bio's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sesen Bio's Scaled Net Operating Assets falls into.

Sesen Bio Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sesen Bio's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(21.008	-	29.249)	/	213.061
=	-0.04

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	178.58	-	157.572
=	21.008

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	29.249	-	0	-	0
=	29.249

Sesen Bio's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2022 )
=	(Operating Assets (Q: Dec. 2022 )	-	Operating Liabilities (Q: Dec. 2022 ))	/	Total Assets (Q: Sep. 2022 )
=	(21.008	-	29.249)	/	201.721
=	-0.04

where

	Operating Assets		(Q: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	178.58	-	157.572
=	21.008

	Operating Liabilities		(Q: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	29.249	-	0	-	0
=	29.249

Sesen Bio Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Sesen Bio's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sesen Bio (STU:PCBK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (STU:PCBK) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.sesenbio.com

Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Sesen Bio (STU:PCBK) Headlines

From GuruFocus

Pacific Continental Corp. (PCBK) President/COO Roger S Busse buys 1,000 Shares

By GuruFocus Research GuruFocus Editor • 10-15-2009

Pacific Continental Corp. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-04-2009

Pacific Continental Corp. (PCBK) CEO Hal Brown buys 5,000 Shares

By GuruFocus Research GuruFocus Editor • 10-15-2009

Pacific Continental Corp. (PCBK) CFO Michael Reynolds sells 1,650 Shares

By GuruFocus Research GuruFocus Editor • 02-22-2010